|DPRM -- Israel Stock|| |
ILS 430.00 0.60 0.14%
D Pharm LTD diagnostics interface makes it easy to digest most current publicly released information about D Pharm as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis D Pharm price relationship with some important fundamental indicators such as market cap and management efficiency.
D Pharm Note
The company recorded loss per share of 0.14. D Pharm LTD had not issued any dividends in recent years. This company had 1:50 split on 2016-02-21. D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel. D Pharm operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. To learn more about D-PHARM call Golan Bitton at 972 8 938 5100 or check out http://www.dpharm.com.
D Pharm LTD Alerts
|D Pharm LTD is not yet fully synchronised with the market data|
|D Pharm LTD generates negative expected return over the last 30 days|
|The company reported revenue of 723K. Net Loss for the year was (814K) with profit before overhead, payroll, taxes, and interest of 723K. |
|D-PHARM has accumulated about 314K in cash with (313K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
The company currently falls under 'Micro-Cap' category with current market capitalization of 26.75M.
The company has Profit Margin (PM) of (112.59) %
which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (100.69) %
which suggests for every $100 dollars of sales it generated a net operating loss of -1.01.
D Pharm LTD has return on total asset (ROA) of (42.09) %
which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) %
meaning that it generated substantial loss on money invested by shareholders.
D Pharm Technical and Predictive Indicators